Overcoming the systemic, structural and cultural issues that lead to poor nutrition is complex, making it even more essential for both private and public investment in food as health programs and policies that have been shown to be effective. The post Food as Health: Shifting from Treatment to Prevention of Diet-Related Disease appeared first on…
We need to continue investing in research for early stage, localized prostate cancer, develop treatments that balance efficacy with quality-of-life considerations, ensure diverse representation in clinical trials, and listen to patients and incorporate their perspectives into treatment development and decision-making. The post Prostate Cancer Management – We Need Better Options for Early-Stage Disease appeared first…
Medical coding startup Arintra raised $21 million in Series A funding to help hospitals and physician groups secure accurate, timely reimbursement. The company’s AI-powered platform automates coding, spots documentation gaps and generates claims tailored to specific payers. The post Arintra Raises $21M to Help Providers Win the Reimbursement Fight appeared first on MedCity News.
Joel Keenan, M.D., owner of York Primary Care in Maine, describes new tools in his eClinicalWorks EHR that are saving him time
This data note reviews our recent polling data that finds that Americans struggle to afford many aspects of health care, including disproportionate shares of uninsured adults, Black and Hispanic adults and those with lower incomes.
Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing. The post Novartis Tries Again in Huntington’s, Putting Up…
Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns. The post Genmab to Pay $8B to Get Its Hands on Merus Head & Neck Cancer…
Environmental Services Unit Director Reginald Pearson buys a few televisions throughout the year to give away as prizes to his team during EVS Week. Two employees won televisions this year; one who had a health problem, the other a floor technician who felt discouraged when he needed to fill in for a housekeeper. For both…
BRISTOL, R.I. — At age 82, Roberta Rabinovitz realized she had no place to go. A widow, she had lost both her daughters to cancer, after living with one and then the other, nursing them until their deaths. Then she moved in with her brother in Florida, until he also died. And so last fall,…
A new analysis shows that individuals with employer insurance could save 41% on their out-of-pocket spending for asthma and COPD inhalers through manufacturer savings. In response to a U.S. Senate investigation into inhaler costs, 3 drug makers voluntarily capped out-of-pocket costs on their brand-name asthma and COPD inhalers.